10-Q: Verve Therapeutics Reports Q1 2025 Financial Results and Provides Business Update

Verve Therapeutics reports increased collaboration revenue and provides updates on its clinical programs in its Q1 2025 financial results.

Summary

• Verve Therapeutics reported a net loss of $31.0 million for the three months ended March 31, 2025, compared to a net loss of $48.7 million for the same period in 2024.
• Collaboration revenue increased to $33.0 million from $5.7 million year-over-year, driven by the Vertex and Lilly agreements.
• Research and development expenses increased to $54.5 million, primarily due to higher employee-related costs and clinical trial expenses.
• The company's cash, cash equivalents, and marketable securities totaled $497.1 million as of March 31, 2025, expected to fund operations into mid-2027.
• Verve is advancing its Heart-2 clinical trial of VERVE-102 and Pulse-1 clinical trial of VERVE-201.
• The company plans to dose the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025, subject to regulatory clearance.
• Verve achieved the candidate selection criteria for VERVE-301 under the Lilly Agreement, triggering a $20.0 million milestone payment.
• Vertex provided notice to terminate the Vertex Agreement, effective in April 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While the company is still operating at a loss, there are positive developments in collaboration revenue, clinical trial progress, and regulatory designations. The strong cash position and extended runway are also positive indicators.

Positives

• Collaboration revenue increased significantly, indicating successful partnerships.
• Strong cash position provides a runway into mid-2027.
• Promising initial data from the Heart-2 trial supports the potential of VERVE-102.
• FDA clearance of the VERVE-102 IND and Fast Track designation expedite development.
• Achievement of a milestone under the Lilly Agreement validates the LPA program.

Negatives

• The company continues to operate at a loss, with a net loss of $31.0 million for Q1 2025.
• Termination of the Vertex Agreement will impact future collaboration revenue.
• Increased research and development expenses may strain financial resources.
• The company is reliant on third parties for manufacturing, research, and clinical testing.

Risks

• Clinical trials may not be successful, and regulatory approvals may be delayed or not obtained.
• Gene editing technology is novel and may have unforeseen safety or efficacy issues.
• The company faces substantial competition in the cardiovascular disease market.
• The company relies on collaborations, which may not be successful.
• The company needs to raise additional capital to fund operations beyond mid-2027.
• Adverse public perception of genetic medicines could negatively impact demand.

Future Outlook

Verve expects to continue to incur significant expenses and increasing operating losses as it advances its programs and product candidates. The company believes its existing cash, cash equivalents, and marketable securities will fund operations into mid-2027.

Management Comments

• The company expects revenue related to the Lilly Agreement to increase as efforts under the collaboration continue.

Industry Context

Verve is operating in the competitive field of genetic medicines for cardiovascular disease, facing competition from established pharmaceutical companies and other biotechnology firms. The company's success depends on its ability to differentiate its products and secure regulatory approvals.

Comparison to Industry Standards

• The report does not provide enough information to make a detailed comparison to industry standards.
• However, the company's focus on gene editing for cardiovascular disease aligns with a growing trend in the pharmaceutical industry.
• Companies like Amgen and Novartis are also developing therapies for similar targets, such as PCSK9 and Lp(a).
• Verve's approach of single-course gene editing medicines differentiates it from traditional chronic therapies.

Legal Proceedings

• The company is currently not a party to any material legal proceedings.

Related Party Transactions

• The board of directors of the Company elected an executive officer of Vertex to the Company's board of directors in June 2024.
• In July 2022, the Company and Vertex entered into the Vertex Agreement.
• In January 2025, Vertex provided the Company with notice to terminate the Vertex Agreement within 90 days for convenience, which resulted in an effective termination date in April 2025.
• During the three months ended March 31, 2025 and 2024, the Company received reimbursements of $ 1.4 million and $ 3.0 million associated with the Vertex Agreement, respectively, which were recorded as revenue.
• During the three months ended March 31, 2025, the Company recognized additional revenue of $ 20.0 million, related to the remaining amounts included in deferred revenue at the notice of termination date, given that the Company does not have any performance obligations under the Vertex Agreement subsequent to March 31, 2025 .

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress will impact shareholder value.
• Employees: The company's ability to attract and retain qualified personnel is critical to its success.
• Patients: The development of new therapies for cardiovascular disease could improve patient outcomes.
• Collaborators: The success of collaborations with Lilly and other partners is important for the company's growth.

Next Steps

• Continue enrollment in the Heart-2 trial of VERVE-102 and Pulse-1 trial of VERVE-201.
• Deliver the opt-in package for the PCSK9 program to Lilly and receive a decision.
• Dose the first patient in the Phase 2 clinical trial of VERVE-102, subject to regulatory clearance.
• Provide a program update on VERVE-201.
• Conduct preclinical studies to support regulatory filings for the initiation of clinical development of VERVE-301.

Key Dates

Keywords

Verve Therapeutics, gene editing, cardiovascular disease, PCSK9, ANGPTL3, LPA, clinical trial, VERVE-102, VERVE-201, VERVE-301, collaboration, Lilly, Vertex, financial results, regulatory approval